Drug development rewards endurance. Biomarker development rewards elegance.
The MeCo Score™ is the first and only clinically validated biomarker test to identify patients with early-stage, high-risk breast cancer who may benefit from FDA-approved antifibrotic therapy (1-4).
In effect, our technology has unlocked an entirely new class of targeted therapies for breast cancer.
Moreover, the MeCo Score™ is drug-agnostic, pathway-agnostic, and even mechanism-of-action-agnostic, thus maximizing its forward compatibility as a companion diagnostic test for second-generation antifibrotic therapies still under development at leading biotech companies.
As a clinical proof-of-concept, our recent 130-patient Phase 2 trial demonstrated that patients with High MeCo Score breast tumors who received nintedanib (antifibrotic therapy) experienced a remarkable benefit: 62% reduced risk of recurrence over 9.7 years (p=0.031) (2,4).
This landmark trial represents a stunning improvement in the long-term survival rate for patients with the most common subtype of breast cancer.
Remarkably, both the magnitude and duration of survival benefit in our trial appear to be unprecedented compared to all previous trials of targeted therapies for early-stage breast cancer (4,5).
Our biomarker platform also demonstrates broad potential for other types of cancer, and we are actively collaborating with some of the world's most prestigious hospitals and cancer centers.
We are on track to fundamentally change the standard of care for hundreds of thousands of cancer patients every year...
Partnerships & Collaborations
Physician-Investor and KOL Affiliations
Major Funding
Other Support
References
[1] Watson, A.W. et al. (2021). Cell Reports. doi: 10.1016/j.celrep.2021.109293
[2] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518
[3] Mouneimne, G. et al. (2025). Cancers. doi: 10.3390/cancers17101632
[4] Event-free survival (EFS) after antifibrotic therapy (nintedanib) + chemotherapy vs. chemotherapy alone.
[5] Based on Hazard Ratios reported from all randomized controlled trials that employed a chemotherapy or endocrine therapy backbone and demonstrated statistically significant results.
Note: The prescribing information for the FDA-approved therapy listed in the MeCo Score test report may not include the associated biomarker; the proposed intended use for the MeCo Score test and its cut-off value are subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the US Food and Drug Administration.
Copyright © 2025 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.